Navigation Links
A New Milestone in Stem Cell Research

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

The Bristol trial will test whether the stem cells will repair heart muscle cells damaged by the heart attack, by preventing late scar formation and hence impaired heart contraction.

Professor Jeremy Pearson, Associate Medical Director of the BHF, said: We hope that this exciting Bristol project will provide information taking us a step nearer to the day when stem cells can be used routinely to help repair damaged hearts.

In a heart attack, part of the heart muscle loses its blood supply (usually due to furring up of the arteries with fatty material) and cells in that part of the heart die, leaving a scar. This reduces the ability of the heart to pump blood around the body.

While the blood supply to the heart can be improved with coronary bypass surgery or angioplasty, thereby reducing the risk of further heart attacks, these techniques do not restore the viability and function of the area already damaged. In 3-6 months after surgery, 20 per cent of patients develop a thinning of the walls of the heart, which in its most extreme form, can lead to congestive heart failure.

Dr Raimondo Ascione, Consultant Cardiac Surgeon, said: I am very grateful to the British Heart Foundation for funding this important trial; the first of its kind worldwide. We have elected to use a very promising stem cell type selected from the patients own bone marrow. This approach ensures no risk of rejection or infection. It also gets around the ethical issues that would result from use of stem cells from embryonic or foetal tissue.

Current treatments aim to keep the patient alive with a heart that is working less efficiently than before the heart attack. Cardiac stem cell therapy aims to repair the damaged h eart as it has the potential to replace the damaged tissue.

In this trial (known as TransACT), all patients will have bone marrow harvested before their heart operation. Then either stem cells from their own bone marrow or a placebo will be injected into the patients damaged hearts during routine coronary bypass surgery. The feasibility and safety of this technique has already been demonstrated.

As a result of the chosen double blind placebo-controlled design, neither the patients nor the surgeon knows whether the patient is going to be injected with stem cells or placebo. This ensures that results are not biased in any way, and is the most powerful way to prove whether or not the new treatment is effective.


'"/>




Related medicine news :

1. Cancer Research: Yet Another Milestone
2. Year 2010 Envisioned to be Milestone Year for Malaria Vaccine
3. Eurand and GSK Reach Development Milestone
4. Kidney Stones - Interesting New Research implicates bacteria as its cause
5. Researchers urge caution in using ear tube surgery
6. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
7. Researchers Scale to assess the Severity of Epilepsy in Kids
8. Research of Ritalin
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. A Compilation of recent Diabetes Research articles
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... ... science and clinical practice of radiosurgery, announced today the publication of a ... registry established to standardize data collection from patients treated with stereotactic radiosurgery ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. Brian ... Medical doctors and PhD scientists will speak to the press on behalf of over ... of an independent vaccine safety commission. , WHERE: , Zenger Room, National Press ...
(Date:3/28/2017)... ORANGE, Calif. (PRWEB) , ... March 28, 2017 ... ... of its leading physicians, Paul Yost, will begin serving as new board chair ... earlier this month. Yost will serve the remainder of soon-to-be former chair Mark ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO ... found in power plant water and steam. , Chlorides and sulfates cause pitting ... leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive porcelain ... smile.” The National Association of Dental Laboratories (NADL) is informing dentists about the ... of when utilizing dental laboratories and technicians that create these veneers. , ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 The National University of Singapore ... analytics company, signed a Memorandum of Understanding (MOU) ... in the region. Under this ... and Technology (BIGHEART) at NUS and Holmusk will ... to healthcare IT and medical device development. These ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
(Date:3/27/2017)... March 27, 2017  Sanderling Ventures, portfolio company, ... a division of Johnson & Johnson. Torax manufactures and ... treatment of gastro-esophageal reflux disease (GERD). The LINK ... technology and the procedure is currently available in ... Torax Medical was founded by Sanderling Ventures, Mayo ...
Breaking Medicine Technology: